Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma

Potent inhibitors of PI3K (GDC-0941) and Src (Saracatinib) exhibit as individual agents, excellent oral anticancer activity in preclinical models and have entered phase II clinical trials in various cancers. We found that PI3K and Src kinases are dysregulated in clear cell renal carcinomas (ccRCCs),...

Descripción completa

Detalles Bibliográficos
Autores principales: Roelants, Caroline, Giacosa, Sofia, Pillet, Catherine, Bussat, Rémi, Champelovier, Pierre, Bastien, Olivier, Guyon, Laurent, Arnoux, Valentin, Cochet, Claude, Filhol, Odile
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059021/
https://www.ncbi.nlm.nih.gov/pubmed/30046388
http://dx.doi.org/10.18632/oncotarget.25700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059021/
https://www.ncbi.nlm.nih.gov/pubmed/30046388
http://dx.doi.org/10.18632/oncotarget.25700

Ejemplares similares